Who will deliver the first in-body CRISPR cure?
In our biotechnology market deck, you will find everything you need to understand the market
SUMMARY
Intellia Therapeutics is the company most likely to deliver the first in-body CRISPR cure, with a possible US launch of lonvo-z in the first half of 2027 if the FDA review stays on track.
Its lead is unusually clear. Intellia has completed a randomized Phase 3 trial, started a rolling FDA application and followed some early patients for as long as three years, while every rival is still dosing, expanding or preparing its first clinical cohort.
Lonvo-z does not repair the mutation that causes hereditary angioedema. It disables KLKB1 to interrupt the disease pathway, so the best description is a functional cure for many patients rather than a genetic correction of the original defect.
The Phase 3 result is the strongest clinical evidence in the field: treated patients had 87% fewer attacks than placebo recipients, and 62% remained free from attacks and long-term preventive therapy during the six-month evaluation period.
Beam Therapeutics is the strongest challenger and the technical leader in true mutation correction. BEAM-302 rewrites the harmful SERPINA1 sequence and has already pushed functional alpha-1 antitrypsin above the commonly used protective threshold at its selected dose.
That distinction is important but does not erase the maturity gap. Beam has strong biomarker data from a small open-label study; Intellia has shown fewer real disease attacks in a controlled pivotal trial.
Lilly's VERVE-102 may eventually create the largest business. Permanent LDL lowering could reach far more patients than rare-disease editing, but cardiovascular medicine also imposes a much tougher safety standard because effective reversible treatments already exist.
Safety does not produce one simple winner. VERVE-102 has the cleanest early record, lonvo-z has the strongest late-stage dataset, and the fatal liver event in Intellia's separate nex-z program will keep regulators focused on platform-wide liver risk.
In-body liver editing should be easier to manufacture and deliver than ex vivo cell therapy because it uses standardized lipid-nanoparticle batches and avoids collecting, shipping and reinfusing each patient's cells. Intellia is closest to proving that operational advantage in the real market.
The ranking can still change, but the burden is now on the challengers. Beam would need unusually fast pivotal execution, while Intellia would need a serious regulatory, manufacturing or safety setback to lose first place before approval.
This market map, featured in our biotechnology market deck, highlights top companies and startups in the biotechnology market
Which companies are really competing to deliver an in-body CRISPR cure?
The real in-body CRISPR field currently has six credible contenders, although only five have treated patients and just one has completed a Phase 3 trial.
We include companies developing permanent DNA edits delivered directly into a patient. Most leading programs send editing machinery to liver cells through lipid nanoparticles. We exclude treatments such as Casgevy and Beam's risto-cel because the patient's cells are removed, edited in a laboratory and reinfused.
Intellia Therapeutics, Beam Therapeutics, Lilly's Verve Therapeutics, CRISPR Therapeutics and Arbor Biotechnologies have dosed patients with in-body editors. Prime Medicine has received its first clinical authorization for an in-body prime-editing treatment and expects to begin dosing during the second half of 2026.
We exclude Tessera Therapeutics, Metagenomi, Chroma Medicine, Ensoma and Tune Therapeutics because their relevant programs have not reached human testing. Excision BioTherapeutics has treated HIV patients, but its initial EBT-101 dose failed to prevent viral rebound in the three participants who interrupted antiretroviral therapy.
Funding also needs careful handling. Intellia, Beam, CRISPR Therapeutics and Prime Medicine have been public companies for years, so their original venture rounds say little about their current financial strength. The figures below show approximate private capital raised before an IPO or acquisition.
| Company | What its leading in-body treatment does | Current stage | Approximate private funding before IPO or acquisition |
|---|---|---|---|
| Intellia Therapeutics | Disables KLKB1 to prevent hereditary angioedema attacks | Phase 3 completed; rolling FDA application underway | $85M |
| Beam Therapeutics | Corrects the PiZ mutation causing alpha-1 antitrypsin deficiency | Phase 1/2; pivotal expansion planned | $222M |
| Lilly / Verve Therapeutics | Disables PCSK9 to lower LDL cholesterol permanently | Phase 1b; Phase 2 planned | $216M |
| CRISPR Therapeutics | Disables ANGPTL3 to lower triglycerides and cholesterol | Phase 1b | About $130M |
| Arbor Biotechnologies | Disables HAO1 to reduce oxalate production in PH1 | Phase 1/2 dose escalation | About $304M |
| Prime Medicine | Corrects ATP7B mutations causing Wilson disease | First clinical trial authorized; dosing expected soon | $315M |
Who is leading the in-body CRISPR race, and who will reach approval first?
Intellia Therapeutics is comfortably ahead today and should deliver the first approved in-body CRISPR treatment unless the FDA finds a major problem with lonvo-z.
Intellia's lonvo-z has completed an 80-patient, randomized and placebo-controlled Phase 3 trial in hereditary angioedema. The trial met its primary endpoint and all major secondary endpoints, the results appeared in the New England Journal of Medicine, and Intellia has started sending sections of its approval application to the FDA.
The company plans to complete its rolling biologics license application during the second half of 2026 and is preparing for a possible United States launch during the first half of 2027.
Beam is the closest serious challenger. BEAM-302 has produced strong biological results in 29 patients and is preparing for a roughly 50-patient pivotal expansion. The FDA has allowed Beam to pursue a possible accelerated approval route based on alpha-1 antitrypsin biomarkers measured over 12 months.
Lilly's VERVE-102 has treated 35 patients and should enter Phase 2 by the end of 2026. CRISPR Therapeutics and Arbor remain in dose-finding studies, while Prime has authorization to begin its first in-body trial but no human results yet.
The gap is plain: Intellia has finished pivotal testing. Every rival is still proving a dose, enrolling a later-stage cohort or preparing its first patients.
If you want more recent data on this point, please see our latest biotechnology market report.
As this chart shows, and as featured in our biotechnology market deck, search interest in biotech has been trending upward
Which in-body CRISPR treatment has shown the strongest clinical results?
Intellia's lonvo-z has produced the strongest clinical results because it has prevented real hereditary angioedema attacks in a randomized Phase 3 trial.
Patients receiving lonvo-z averaged 0.26 attacks per month during the main evaluation period, compared with 2.10 attacks among patients receiving a placebo. That equals an 87% reduction. The average experience changed from approximately one attack every two weeks to one every four months.
Sixty-two percent of lonvo-z patients experienced no attacks and required no long-term preventive treatment during the six-month evaluation window. Only 11% of placebo patients achieved the same result.
Beam has shown the most impressive early biological correction. At the selected 60-milligram dose, BEAM-302 raised mean alpha-1 antitrypsin to 16.1 micromolar, above the widely used protective threshold of 11 micromolar. Corrected M-AAT made up 94% of circulating AAT, while harmful Z-AAT fell by 84%.
Those Beam results could eventually translate into fewer cases of emphysema, cirrhosis and liver transplantation. For now, Beam has measured proteins in a small open-label study, while Intellia has measured disease attacks against a placebo.
Lilly's VERVE-102 lowered LDL cholesterol by an average of 62% at its highest dose and reduced PCSK9 by 88%, with effects lasting up to 18 months. CRISPR Therapeutics reported triglyceride reductions of up to 84% with CTX310. Both results are large, though neither trial was designed to prove fewer heart attacks, strokes or deaths.
Is Intellia's lonvo-z really an in-body CRISPR cure?
Lonvo-z already looks like a functional cure for many hereditary angioedema patients, even though Intellia does not repair the mutation that originally caused the disease.
Hereditary angioedema is usually caused by defects affecting the C1 inhibitor pathway. Lonvo-z edits KLKB1 instead, reducing kallikrein and the excess bradykinin that triggers swelling.
For patients, the outcome may matter more than the molecular route. Someone who previously lived with unpredictable swelling attacks and regular preventive medication may receive one infusion and then remain free from both. In the Phase 3 trial, 62% of treated patients reached that combined outcome during the six-month evaluation period.
The earlier Phase 1 group strengthens the cure argument. All ten patients remained free from attacks and preventive therapy for a median of 23 months, while their mean attack rate stayed 98% below baseline through follow-up extending as long as three years.
It is not a guaranteed cure. More than one-third of the Phase 3 treatment group experienced at least one attack or needed additional therapy during the evaluation period. "Functional cure for a majority of treated patients" is the most accurate description currently.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, illustrates yearly venture capital funding for biotechnology startups
Which in-body CRISPR treatment has the best durability evidence?
Intellia currently has the best durability evidence because lonvo-z combines three years of follow-up with sustained control of actual disease attacks.
The earliest lonvo-z patients maintained a 98% mean reduction in hereditary angioedema attacks for up to three years. All ten experienced extended periods without attacks or long-term preventive medicine.
VERVE-102 has maintained reductions in PCSK9 and LDL cholesterol for up to 18 months. BEAM-302 patients have also been followed for up to 18 months, with the selected 60-milligram group maintaining protective AAT levels for as long as 12 months.
The evidence is not equivalent. Intellia has shown durable freedom from attacks; Beam and Lilly have shown durable biomarkers. Those biomarkers are meaningful, but long-term disease outcomes remain unproven.
Which in-body CRISPR treatment looks safest right now?
Lilly's VERVE-102 has the cleanest early safety profile, while lonvo-z has the strongest late-stage safety dataset for one specific in-body CRISPR treatment.
Among 35 VERVE-102 participants, Lilly reported no treatment-related serious adverse events and no dose-limiting toxicities. The main treatment-related problems were low-grade infusion reactions and fatigue.
Lonvo-z produced similarly reassuring results at a later stage. Intellia reported no treatment-related serious adverse events in the 52 patients assigned to lonvo-z during HAELO's main evaluation period. Reported events were mild or moderate, with infusion reactions, headache and fatigue appearing most often.
Intellia's broader platform still carries the field's biggest unresolved safety concern. A patient in the separate nex-z Phase 3 program developed severe liver abnormalities and later died. The FDA placed two nex-z trials on hold before allowing them to restart with stricter liver testing, steroid guidance and tighter eligibility criteria.
Beam reported no serious adverse events or dose-limiting toxicities among the 26 patients who received one BEAM-302 dose. During an attempt at a second dose, one of three patients developed a Grade 4 ALT increase and a Grade 3 AST increase. The abnormalities were asymptomatic and occurred without increased bilirubin, but Beam chose to advance a single 60-milligram dose.
VERVE-102 therefore has the cleanest early record, while lonvo-z has the more convincing late-stage evidence. The nex-z death prevents Intellia from claiming a broader platform-wide safety advantage.
This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology
Which company is actually correcting a disease-causing mutation inside the body?
Beam Therapeutics is currently the clinical leader in true mutation correction because BEAM-302 rewrites the faulty SERPINA1 sequence responsible for severe alpha-1 antitrypsin deficiency.
Most advanced in-body treatments work by disabling a gene. Lonvo-z switches off KLKB1, VERVE-102 switches off PCSK9, CTX310 switches off ANGPTL3, and Arbor's ABO-101 switches off HAO1.
BEAM-302 changes the harmful PiZ version of SERPINA1 into a sequence that produces functional M-AAT. The treatment also reduces the toxic Z-AAT protein that accumulates in the liver, potentially addressing both the lung and liver sides of the disease.
One patient's response during a respiratory infection was especially interesting. Total AAT rose to approximately 30 micromolar, while 95% remained corrected M-AAT. That suggests the edited gene could still respond to normal inflammatory signals.
Prime Medicine is Beam's most ambitious technical challenger. Prime's PM577a aims to correct the H1069Q mutation in ATP7B, a common cause of Wilson disease in North America and Europe. Prime editing can make a wider range of DNA changes than base editing, but Prime has not yet produced human results.
If you want more recent data on this point, please see our latest biotechnology market report.
Which in-body CRISPR treatment could create the most value for patients?
Intellia offers the clearest near-term patient value, while Lilly and Verve are pursuing a much larger long-term opportunity.
A successful lonvo-z treatment could replace years of hereditary angioedema medication with one outpatient infusion. Seventy-one percent of HAELO participants were taking long-term preventive therapy before the trial and had to stop it before treatment. At the data cutoff, patients who received lonvo-z remained off long-term prophylaxis.
BEAM-302 could address a different treatment gap. Current AAT augmentation therapy requires regular infusions, mainly targets the protein deficiency affecting the lungs and does little to remove the toxic protein accumulating in the liver. Beam has shown that one edit can raise functional AAT while sharply reducing mutant Z-AAT.
VERVE-102 has the largest potential population. Heterozygous familial hypercholesterolemia affects approximately one person in every 200 to 250, and coronary artery disease affects more than 300 million people worldwide. Lilly initially plans to target people with inherited or premature cardiovascular disease whose LDL remains too high despite treatment.
The commercial opportunity is enormous, but so is the safety burden. Patients with high cholesterol can already choose inexpensive statins, injectable PCSK9 inhibitors and other long-acting treatments. VERVE-102 will need exceptional long-term safety to justify a permanent edit.
No company has published a credible commercial price for these treatments. Intellia has the strongest visible patient proposition today; Lilly has the biggest market if broad cardiovascular editing becomes acceptable.
This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups
Which company can manufacture and launch an in-body CRISPR treatment at scale?
Intellia is best prepared for a near-term launch, while Lilly would have the strongest global delivery machine if VERVE-102 reaches the market.
In-body liver editing has an operational advantage over ex vivo cell therapy. Manufacturers can produce standardized batches of lipid nanoparticles, and hospitals do not need to collect, ship, edit and reinfuse each patient's cells.
Intellia has already run a global Phase 3 trial, established its commercial manufacturing process for the FDA application and begun building launch infrastructure. Including an additional public offering completed after the first quarter, Intellia expects its existing resources to fund operations into 2028 and beyond the planned lonvo-z launch.
No in-body CRISPR treatment currently has product revenue, paying customers or repeat orders. Intellia is still the closest to real commercial traction because it has completed pivotal testing, started its FDA application and outlined a launch window.
Beam held about $1.21 billion in cash and investments at the end of the first quarter, enough to fund its current plans into mid-2029. CRISPR Therapeutics held approximately $2.44 billion, giving it the strongest independent balance sheet.
Prime Medicine reported $149.2 million in cash, investments and restricted cash, providing runway into 2027. Additional financing or a partnership will probably be needed before its in-body programs reach late-stage development.
Lilly gives Verve access to a global pharmaceutical organization, including clinical operations, manufacturing, reimbursement teams and relationships with cardiologists. That advantage will matter once VERVE-102 has enough evidence for a large pivotal program.
Which company has the strongest competitive moat in in-body CRISPR?
Intellia has the strongest moat today because completed Phase 3 data, regulatory progress and multi-year patient follow-up are harder to copy than the basic idea of editing a liver gene.
Several companies can package messenger RNA and guide RNA inside lipid nanoparticles and send them to the liver. Clinical evidence is more difficult to reproduce. A rival cannot quickly recreate three years of patient follow-up, a completed randomized trial or a regulator-reviewed manufacturing file.
Beam has the strongest scientific differentiation. Base editing changes individual DNA letters without making a double-stranded break, and BEAM-302 has shown direct correction of a pathogenic mutation in patients.
Prime's potential moat comes from editing range. Its technology can theoretically correct mutations that standard CRISPR cutting and base editing cannot reach. Prime now has to prove that its larger editing machinery can reach enough human liver cells and make the intended change safely.
Lilly and Verve benefit from a delivery system designed to enter liver cells through two receptors rather than depending entirely on the LDL receptor. CRISPR Therapeutics has scale, cash and a broad cardiovascular pipeline targeting ANGPTL3, lipoprotein(a) and angiotensinogen.
For now, Intellia owns the hardest-to-copy asset: late-stage human evidence.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies
Which in-body CRISPR company has gained the most momentum lately?
Intellia has gained the most consequential momentum because lonvo-z moved from promising long-term data to successful pivotal evidence and active regulatory review.
Intellia showed durable attack control in early patients, completed a global Phase 3 trial, produced a large placebo-adjusted effect, secured publication in the New England Journal of Medicine and began preparing for launch. Each step removed a different source of risk.
Beam ranks second. Its BEAM-302 dataset expanded to 29 patients, the company selected the 60-milligram dose and established a potential accelerated approval path with the FDA. Beam has also received clearance for BEAM-304 in phenylketonuria.
Lilly and Verve have accelerated as well. The VERVE-102 dataset expanded to 35 participants, follow-up reached 18 months, the highest dose produced a 62% average LDL reduction, and Lilly committed to beginning Phase 2 by the end of 2026.
Prime obtained the first clinical authorization for an in-body prime-editing therapy and plans to begin its Wilson disease study during the second half of 2026. CRISPR Therapeutics continues to expand its pipeline, but CTX310 remains in Phase 1b and its next major data update is still pending.
What could change the in-body CRISPR ranking?
Intellia would lose first place only through a serious regulatory setback, an unexpected lonvo-z safety problem or unusually fast execution from Beam.
The clearest risk is safety scrutiny. Although lonvo-z's Phase 3 record looks reassuring, the fatal event in the separate nex-z program will make regulators examine liver toxicity, patient selection and monitoring closely. A request for longer follow-up or additional manufacturing work could delay the review.
Adoption could also disappoint after approval. Hereditary angioedema patients already have effective preventive medicines, and some may prefer a treatment they can stop over an irreversible DNA edit.
Beam has the best chance of narrowing the gap. Its planned pivotal expansion is relatively small, and the proposed primary endpoint uses biomarkers measured over 12 months. Strong replication across roughly 50 additional patients could move BEAM-302 toward an approval application quickly.
Lilly could eventually jump ahead commercially. If VERVE-102 maintains large LDL reductions, avoids rare severe events in much larger trials and eventually reduces cardiovascular events, its market would be far larger than those targeted by Intellia or Beam.
Prime remains the long-term wildcard. Successful correction of ATP7B in Wilson disease patients would validate a more versatile editing system, but initial human data are not expected until 2027.
This chart, featured in our biotechnology market deck, breaks down revenue across customer segments in the biotechnology market
Which startups are actually ahead in in-body CRISPR?
Intellia Therapeutics ranks first in in-body CRISPR by a wide margin, with Beam as the strongest challenger and Lilly's Verve program as the best bet on a much larger future market.
Intellia has the field's most mature evidence: randomized clinical efficacy, multi-year durability, a manageable one-time outpatient treatment and a realistic route to approval.
Beam ranks second because BEAM-302 has achieved something more technically ambitious than lonvo-z: direct correction of a disease-causing mutation inside patients. Its clinical evidence remains smaller and earlier, but the selected dose produced a consistent pattern across functional protein, mutant protein and biological regulation.
Lilly and Verve take third place. VERVE-102 has a clean early safety profile, durable LDL reduction and access to Lilly's development and commercial resources. The cardiovascular opportunity could eventually dwarf the rare-disease programs ahead of it.
CRISPR Therapeutics ranks fourth. It has the most cash, experience with an approved ex vivo CRISPR medicine and the broadest cardiovascular editing pipeline. CTX310's early results are credible, but the company has not yet converted that platform strength into a late-stage in-body program.
Arbor ranks fifth because ABO-101 has entered patients with a distinct Cas12i2 editor and a clear rare-disease development route. Prime ranks sixth because its first in-body trial has been authorized, but its advantage remains technological until human results appear.
Intellia is currently most likely to deliver the first in-body CRISPR cure, probably through a functional cure for hereditary angioedema. Beam is best placed to deliver the first approved treatment that genuinely corrects a disease-causing mutation. Lilly and Verve have the strongest chance of turning in-body editing into a very large cardiovascular business later.
| Rank | Company | Why it ranks here |
|---|---|---|
| 1 | Intellia Therapeutics | The only contender with completed pivotal evidence, multi-year clinical durability and an approval application in progress |
| 2 | Beam Therapeutics | The leader in direct mutation correction, with strong human biomarkers and a defined pivotal route |
| 3 | Lilly / Verve Therapeutics | The strongest early cardiovascular program, backed by Lilly and aimed at the largest eventual patient population |
| 4 | CRISPR Therapeutics | Exceptional financial strength and a broad pipeline, but its in-body programs remain early |
| 5 | Arbor Biotechnologies | A differentiated editor is now being tested in patients, although meaningful efficacy data are still missing |
| 6 | Prime Medicine | The broadest editing potential among the group, with its first in-body clinical study only now beginning |
If you want more recent data on this point, please see our latest biotechnology market report.
OUR METHODOLOGY
This analysis asks which company is most likely to deliver the first approved in-body CRISPR cure. We compare the leading programs across clinical maturity, quality of efficacy evidence, durability, safety, regulatory progress, manufacturing readiness, scientific differentiation, patient value, commercial scale and competitive position.
We define in-body, or in vivo, CRISPR treatment as a permanent DNA edit delivered directly into the patient. We exclude ex vivo treatments such as Casgevy and risto-cel, where cells are removed, edited in a laboratory and then reinfused.
Each dimension was assessed separately before the overall ranking was set. We gave more weight to randomized and pivotal clinical evidence than to small open-label studies, more weight to patient outcomes than to biomarkers, and more weight to regulatory action and completed execution than to announced plans.
The word "cure" is used carefully. A treatment can qualify as a functional cure when one administration produces sustained freedom from disease and ongoing preventive therapy, even if it does not repair the mutation that originally caused the condition. Direct mutation correction is treated as a separate scientific advantage.
Funding figures refer to approximate private capital raised before an IPO or acquisition. They are included as historical context, not as a current measure of financial strength. For public companies, recent cash and investment balances are more useful when judging development runway and launch readiness.
Safety was assessed at both the individual-program and platform levels. A clean record in one trial carries real weight, but serious events in another program using related delivery or editing technology still affect how regulators and patients may view the broader platform.
We prioritized first-hand clinical and regulatory evidence: peer-reviewed trial publications, company trial presentations and press releases, FDA decisions, registered study records, SEC filings and formal investor disclosures. We also used specialist medical organizations to check disease prevalence, treatment context and the meaning of key biomarkers.
Key sources include Intellia Therapeutics and its press releases, The New England Journal of Medicine, Beam Therapeutics and its news and publications, Verve Therapeutics, Eli Lilly's newsroom, CRISPR Therapeutics and its news and events, Arbor Biotechnologies, and Prime Medicine.
Regulatory, trial and financial checks relied on the U.S. Food and Drug Administration, ClinicalTrials.gov, and SEC EDGAR. Supporting scientific and disease context came from PubMed, Nature Biotechnology, Nature Medicine, the American Heart Association, the Alpha-1 Foundation, the National Organization for Rare Disorders, the National Institutes of Health, the European Medicines Agency, and MedlinePlus.
This chart, featured in our biotechnology market deck, shows how at-home genetic testing technology has evolved over time
Related blog posts
- Gene editing: which startup is ahead?
- RNA medicines: which startup is ahead?
- Which startup looks most promising in reversing cellular aging?
